S. Hall

发表

Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors

C. Ernest, S. Hall, David R. Jones, 2005, Journal of Pharmacology and Experimental Therapeutics.

Correlation of serum concentrations of ibuprofen stereoisomers with clinical response in the treatment of hip and knee osteoarthritis.

K. Brandt, D. Brater, B. Katz, 1992, The Journal of rheumatology.

Bimodal distribution of renal cytochrome P450 3A activity in humans.

P. Watkins, S. Wrighton, J. Gorski, 1996, Molecular pharmacology.

Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.

Adam J Schwarz, Peng Yu, E. Siemers, 2012, Journal of Alzheimer's disease : JAD.

Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans.

Lang Li, J. Gorski, Zaiqi Wang, 2003, British journal of clinical pharmacology.

Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a co‐regulated substrate, mephobarbital

R. Branch, S. Hall, G. Wilkinson, 1986, Clinical pharmacology and therapeutics.

Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding.

G R Wilkinson, S D Hall, R. Branch, 1988, The Journal of pharmacology and experimental therapeutics.

The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity

Shiew-Mei Huang, L. Lesko, J. Gorski, 2001, Clinical pharmacology and therapeutics.

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin

J. Gorski, B. Haehner‐Daniels, S. Hall, 1998, Clinical pharmacology and therapeutics.

Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population‐Modeling Approach

L. Aarons, A. Galetin, A. Rostami-Hodjegan, 2014, Clinical pharmacology and therapeutics.

SELECTIVE METABOLISM OF VINCRISTINE IN VITRO BY CYP3A5

Jennifer B Dennison, P. Kulanthaivel, S. Hall, 2006, Drug Metabolism and Disposition.

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

Ann Daly, Jatinder Lamba, M. Boguski, 2001, Nature Genetics.

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

S D Hall, S. Wrighton, D. Jones, 1994, Biochemical pharmacology.

The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants.

J. Hudson, M. Boguski, M. Relling, 2001, Pharmacogenetics.

Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.

K. Tashima, L. Szczech, N. Franceschini, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Genetically determined polymorphisms in drug oxidation

R. Branch, S. Hall, E. Jacqz, 1986, Hepatology.

The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity

David A. Flockhart, Zeruesenay Desta, Stephen D. Hall, 2003, Journal of Pharmacology and Experimental Therapeutics.

The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis

L. Szczech, S. Koletar, Samir K. Gupta, 2008, AIDS.

CYP2B6 Pharmacogenetics–Based In Vitro–In Vivo Extrapolation of Efavirenz Clearance by Physiologically Based Pharmacokinetic Modeling

Lang Li, Z. Desta, S. Quinney, 2013, Drug Metabolism and Disposition.

DMD051755 2004..2011

S. Hall, Z. Desta, S. Quinney, 2013 .

Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines.

D. Foster, D. Murry, S. Hall, 2006, Biochemical pharmacology.

Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily.

S. Wrighton, D. Jones, J. Gorski, 1994, Biochemical pharmacology.

Quantitative Structure − Activity Relationship Models of Clinical Pharmacokinetics : Clearance and Volume of Distribution

Vijay K. Gombar, Stephen D. Hall, V. Gombar, 2013 .

The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis

L. Szczech, S. Koletar, Samir K. Gupta, 2008, AIDS.

Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.

E. Siemers, R. Dean, A. Schwarz, 2012, Journal of Alzheimer's disease : JAD.

Effect of cirrhosis and liver transplantation on the gender difference in QT interval.

Lang Li, N. Chalasani, D. Flockhart, 2005, The American journal of cardiology.

The role of coenzyme A in the biotransformation of 2-arylpropionic acids.

S. Hall, X. Quan, S. Hall, 1994, Chemico-biological interactions.

Determination of the epimeric composition of ibuprofenyl-CoA.

T. Tracy, S. Hall, S. Hall, 1991, Analytical biochemistry.

Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions

Xu Han, J. Marc Overhage, Lang Li, 2012, PLoS Comput. Biol..

The Impact of the Hepatocyte-to-Plasma pH Gradient on the Prediction of Hepatic Clearance and Drug-Drug Interactions for CYP2D6 Substrates

M. Mohutsky, S. Hall, D. Bedwell, 2016, Drug Metabolism and Disposition.

The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity

W. Ambrosius, J. Gorski, B. Haehner‐Daniels, 2003, Clinical pharmacology and therapeutics.

Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: A comparison with nonalcoholics

N. Chalasani, J. Gorski, S. Hall, 2005, Hepatology.

Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes.

B. Ring, S. Wrighton, S. Hall, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Physiologically‐Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid‐to‐Lactone Conversion

K. Hillgren, M. Posada, L. Tham, 2019, CPT: pharmacometrics & systems pharmacology.

Stereoselective arylpropionyl-CoA thioester formation in vitro.

S. Hall, M. Knadler, S. Hall, 1990, Chirality.

Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes.

S. Wrighton, A. Rettie, B. Haehner‐Daniels, 2000, Biochemical pharmacology.

Acute and Chronic Effects of Nonsteroidal Antiinflammatory Drugs on Glomerular Filtration Rate in Elderly Patients

M. Murray, S. Hall, D. Brater, 1995, The American journal of the medical sciences.

Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination.

S. Hall, D. Brater, D. Rudy, 1999, British journal of clinical pharmacology.

Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis

N. Chalasani, D. Crabb, J. Gorski, 2003, Hepatology.

Molecular and physical mechanisms of first-pass extraction.

R. Fontana, P. Watkins, L. Benet, 1999, Drug metabolism and disposition: the biological fate of chemicals.

CHAPTER 98 – Disposition and Dose Requirements of Drugs in Renal Insufficiency

S. Hall, D. Brater, S. Hall, 2008 .

Hepatic Organic Anion Transporting Polypeptide–Mediated Clearance in the Beagle Dog: Assessing In Vitro–In Vivo Relationships and Applying Cross-Species Empirical Scaling Factors to Improve Prediction of Human Clearance

K. Hillgren, A. Galetin, J. Houston, 2018, Drug Metabolism and Disposition.

The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity.

S. Wrighton, J. Gorski, S. Hall, 2002, British journal of clinical pharmacology.

The interaction between St John's wort and an oral contraceptive

Shiew-Mei Huang, J. Gorski, Zaiqi Wang, 2003, Clinical pharmacology and therapeutics.

Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.

Joe Kesterson, N. Chalasani, H. Aljadhey, 2004, Gastroenterology.

A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors

Menggang Yu, B. Schneider, C. Sweeney, 2010, Cancer Chemotherapy and Pharmacology.

Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach

L. Aarons, A. Galetin, A. Rostami-Hodjegan, 2015, Pharmaceutical Research.

Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population

L. Aarons, A. Galetin, S. Hall, 2017, Pharmacogenetics and genomics.

Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.

B. Ring, S. Wrighton, S. Strom, 1998, Pharmacogenetics.

The Impact of the Hepatocyte-to-Plasma pH Gradient on the Prediction of Hepatic Clearance and Drug-Drug Interactions for CYP2D6 Substrates

M. Mohutsky, D. Bedwell, K. Ruterbories, 2016, Drug Metabolism and Disposition.

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

B. Ring, S. Wrighton, S. Hall, 2002, Drug metabolism and disposition: the biological fate of chemicals.

COMPARATIVE METABOLIC CAPABILITIES OF CYP 3 A 4 , CYP 3 A 5 , AND CYP 3 A 7

B. Ring, S. Wrighton, S. Hall, 2002 .

The effect of hormone replacement therapy on CYP3A activity

S. Wrighton, J. Gorski, Zaiqi Wang, 2000, Clinical pharmacology and therapeutics.

The effect of rifampin administration on the disposition of fexofenadine

B. Haehner‐Daniels, S. Hall, M. Hamman, 2001, Clinical pharmacology and therapeutics.

Interaction between midazolam and clarithromycin in the elderly.

J. Gorski, S. Hall, S. Quinney, 2008, British journal of clinical pharmacology.

Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin.

A. Li, J. Gorski, S. Hall, 1997, Chemico-biological interactions.

Quantitative Prediction of CYP3A4‐ and CYP3A5‐Mediated Drug Interactions

S. Hall, R. Vuppalanchi, G. Dickinson, 2020, Clinical pharmacology and therapeutics.

The Relative Contributions of CYP3A4 and CYP3A5 to the Metabolism of Vinorelbine

Jennifer B Dennison, S. Hall, C. Hadden, 2013, Drug Metabolism and Disposition.

Cytochrome P450 3A5 Genotype is Associated with Verapamil Response in Healthy Subjects

Lang Li, R. Kovacs, S. Hall, 2007, Clinical pharmacology and therapeutics.

Effect of CYP3A5 Expression on Vincristine Metabolism with Human Liver Microsomes

Jennifer B Dennison, S. Hall, J. Renbarger, 2007, Journal of Pharmacology and Experimental Therapeutics.

Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity.

N. Chalasani, S. Wrighton, S. Hall, 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

DIFFERENTIAL MECHANISM-BASED INHIBITION OF CYP3A4 AND CYP3A5 BY VERAPAMIL

S. Hall, David R. Jones, Ying-hong Wang, 2005, Drug Metabolism and Disposition.

Inhibition of Human Intestinal Wall Metabolism by Macrolide Antibiotics: Effect of Clarithromycin on Cytochrome P450 3A4/5 Activity and Expression

N. Chalasani, T. Skaar, J. Gorski, 2005, Clinical pharmacology and therapeutics.

Effect of CYP 3 A 5 Expression on Vincristine Metabolism with Human Liver Microsomes

Jennifer B Dennison, S. Hall, J. Renbarger, 2007 .

DIFFERENTIAL MECHANISM-BASED INHIBITION OF CYP 3 A 4 AND CYP 3 A 5 BY VERAPAMIL

S. Hall, David R. Jones, Ying-hong Wang, 2005 .

Impact of Heterotropic Allosteric Modulation on the Time-Dependent Inhibition of Cytochrome P450 3A4

D. Bedwell, T. Abraham, L. Rougée, 2023, Drug Metabolism and Disposition.

Prediction of In Vivo Clearance and Associated Variability of CYP2C19 Substrates by Genotypes in Populations Utilizing a Pharmacogenetics-Based Mechanistic Model

Yingying Guo, B. Steere, J. Baker, 2015, Drug Metabolism and Disposition.

The Effect of Echinacea (Echinacea purpurea Root) on Cytochrome P450 Activity in Vivo

Shiew-Mei Huang, J. Gorski, S. Hall, 2004, Clinical pharmacology and therapeutics.

The interaction of diltiazem with lovastatin and pravastatin

S. Hall, David R. Jones, D. Brater, 1998, Clinical pharmacology and therapeutics.

Drug interactions with botanical products

Shiew-Mei Huang, S. Hall, Y. F. Lam, 2006 .

Impaired hepatic elimination of paranitrophenol and its metabolites in the rat following chronic ethanol pretreatment.

R. Branch, S. Hall, S. Schenker, 1989, Alcoholism, clinical and experimental research.

Variable Furosemide Absorption and Poor Predictability of Response in Elderly Patients

M. Murray, S. Hall, D. Brater, 1997, Pharmacotherapy.

Enantioselective effects of experimental diabetes mellitus on the metabolism of ibuprofen.

S. Hall, X. Oian, 1995, The Journal of pharmacology and experimental therapeutics.

Enantioselective disposition of ibuprofen in elderly persons with and without renal impairment.

D. Brater, A. C. Rudy, P. Knight, 1995, The Journal of pharmacology and experimental therapeutics.

Modulation of enantioselective metabolism and inversion of ibuprofen by xenobiotics in isolated rat hepatocytes.

Q. Xiaotao, S. Hall, 1993, The Journal of pharmacology and experimental therapeutics.

Lack of presystemic inversion of (R)‐ to (S)‐ibuprofen in humans

S. Hall, D. Brater, A. C. Rudy, 1993, Clinical pharmacology and therapeutics.

Variability in the Disposition of Ibuprofen Enantiomers in Osteoarthritis Patients

S. Hall, A. C. Rudy, J. Bradley, 1992, Therapeutic drug monitoring.

Metabolic inversion of (R)-ibuprofen. Epimerization and hydrolysis of ibuprofenyl-coenzyme A.

T. Tracy, S. Hall, 1992, Drug metabolism and disposition: the biological fate of chemicals.

Metabolic inversion of (R)-ibuprofen. Formation of ibuprofenyl-coenzyme A.

T. Tracy, S. Hall, D. P. Wirthwein, 1993, Drug metabolism and disposition: the biological fate of chemicals.

Pulmonary inversion of 2-arylpropionic acids: influence of protein binding.

S. Hall, M. Hassanzadeh-Khayyat, M. Knadler, 1992, Chirality.

Predictions of Cytochrome P450-Mediated Drug-Drug Interactions Using Cryopreserved Human Hepatocytes: Comparison of Plasma and Protein-Free Media Incubation Conditions

S. Wrighton, M. Mohutsky, J. Mao, 2012, Drug Metabolism and Disposition.

The interaction of diltiazem with simvastatin

S. Hall, D. Brater, Omaima Mousa, 2000, Clinical pharmacology and therapeutics.

Drug–Drug Interaction Prediction Assessment

Lang Li, Lang Li, S. Hall, 2009, Journal of biopharmaceutical statistics.

Inhibition of CYP3A by Erythromycin: In Vitro-In Vivo Correlation in Rats

R. Kimura, S. Quinney, David R. Jones, 2010, Drug Metabolism and Disposition.

Mechanistic understanding of the phase behavior of supersaturated solutions of poorly water‐soluble drugs

M. Mohutsky, M. Posada, S. Hall, 2018, International journal of pharmaceutics.

Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023).

M. Mitchell, S. Hall, J. Witcher, 2015, Journal of pharmaceutical sciences.

Monitoring the Phase Behavior of Supersaturated Solutions of Poorly Water-Soluble Drugs Using Fluorescence Techniques.

M. Mohutsky, Francesco Tres, L. Taylor, 2018, Journal of pharmaceutical sciences.

Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen.

L. Li, L. Pedersen, J. Goldstein, 1998, Archives of biochemistry and biophysics.

High-performance liquid chromatographic analysis of the enantiomers of flurbiprofen and its metabolites in plasma and urine.

S. Hall, M. Knadler, S. Hall, 1989, Journal of chromatography.

Prediction of Renal Transporter Mediated Drug-Drug Interactions for Pemetrexed Using Physiologically Based Pharmacokinetic Modeling

Maria M. Posada, Stephen D. Hall, K. Hillgren, 2015, Drug Metabolism and Disposition.

Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model

Andy Z. X. Zhu, Yuan Chen, E. Schuck, 2019, CPT: pharmacometrics & systems pharmacology.

Physiologically based pharmacokinetic modeling to understand the observed drug–drug interaction of LY2623091 with CYP3A inhibitors itraconazole and diltiazem

M. Posada, S. Hall, G. Dickinson, 2017 .

Prediction of CYP3A-Mediated Drug-Drug Interactions Using Human Hepatocytes Suspended in Human Plasma

Jialin Mao, S. Wrighton, M. Mohutsky, 2011, Drug Metabolism and Disposition.

Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions.

M. Mohutsky, S. Hall, S. Hall, 2021, Methods in molecular biology.

Irreversible enzyme inhibition kinetics and drug-drug interactions.

M. Mohutsky, S. Hall, S. Hall, 2014, Methods in molecular biology.

Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.

D. Jones, J. Gorski, S. Hall, 1999, The Journal of pharmacology and experimental therapeutics.

Integration of In Vitro Binding Mechanism Into the Semiphysiologically Based Pharmacokinetic Interaction Model Between Ketoconazole and Midazolam

Lang Li, S. Hall, S. Quinney, 2013, CPT: Pharmacometrics & Systems Pharmacology.

STOCHASTIC PREDICTION OF CYP3A-MEDIATED INHIBITION OF MIDAZOLAM CLEARANCE BY KETOCONAZOLE

Jenny Y Chien, S. Wrighton, J. Chien, 2006, Drug Metabolism and Disposition.

Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: Effects of transjugular intrahepatic portosystemic shunts

N. Chalasani, J. Gorski, S. Hall, 2001, Hepatology.

Effect of Rosiglitazone on Serum Liver Biochemistries in Diabetic Patients with Normal and Elevated Baseline Liver Enzymes

N. Chalasani, S. Hall, E. Teal, 2005, The American Journal of Gastroenterology.

Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies

S. Hall, J. W. Higgins, A. Ke, 2014, Clinical pharmacology and therapeutics.

Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily.

S. Wrighton, D. Jones, J. Gorski, 1999, Xenobiotica; the fate of foreign compounds in biological systems.

Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone.

S. Wrighton, D. Jones, J. Gorski, 1997, Xenobiotica; the fate of foreign compounds in biological systems.

Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites

S. Grimm, D. Jones, S. Hall, 2002, Xenobiotica; the fate of foreign compounds in biological systems.

Mechanism-Based Inactivation of CYP 3 A by HIV Protease Inhibitors

C. Ernest, S. Hall, David R. Jones, 2005 .

BASED INACTIVATION OF CYTOCHROME P 450 3 A ( CYP 3 A ) BY HIV PROTEASE INHIBITORSa

C. Ernest, S. Hall, David R. Jones, 2004 .

N. Chalasani, J. Gorski, R. Galinsky, 2002 .

Mechanism-Based Inhibition of Human Cytochromes P450: In Vitro Kinetics and In Vitro—In Vivo Correlations

S. Hall, David R. Jones, S. Hall, 2001 .

Stereoselective disposition of flurbiprofen in normal volunteers.

S. Hall, D. Brater, M. Knadler, 1992, British journal of clinical pharmacology.

Intravenous diltiazem and CYP3A-mediated metabolism.

D. Jones, S. Hall, D. Brater, 2000, British journal of clinical pharmacology.

Apparent High CYP3A5 Expression Is Required for Significant Metabolism of Vincristine by Human Cryopreserved Hepatocytes

Jennifer B Dennison, S. Wrighton, M. Mohutsky, 2008, Journal of Pharmacology and Experimental Therapeutics.

Computational Approaches That Predict Metabolic Intermediate Complex Formation with CYP3A4 (+b5)

Sean Ekins, Lang Li, S. Ekins, 2007, Drug Metabolism and Disposition.

Drug Interaction Involving Direct or Indirect Cytokine Modulation Should Be Investigated in Select Circumstances

D. Coutant, S. Hall, 2018, Journal of clinical pharmacology.

Disease–Drug Interactions in Inflammatory States via Effects on CYP‐Mediated Drug Clearance

S. Hall, D. Coutant, S. Hall, 2018, Journal of clinical pharmacology.

[Principles of clinical pharmacology].

Shiew-Mei Huang, V. V. Zakusov, V V Zakusov, 1974, Terapevticheskii arkhiv.

Drug-induced QT Prolongation in Cirrhotic Patients With Transjugular Intrahepatic Portosystemic Shunt

N. Chalasani, J. Gorski, S. Hall, 2011, Journal of clinical gastroenterology.

High-performance liquid chromatographic determination of the stereoisomeric metabolites of ibuprofen.

A. C. Rudy, K. S. Anliker, S. Hall, 1990, Journal of chromatography.

The assessment of bioavailability in the presence of nonlinear elimination

S. Hall, G. Wilkinson, C. Mcallister, 1988, Journal of Pharmacokinetics and Biopharmaceutics.

Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition.

F. Guengerich, S. Hall, R. Knodell, 1987, The Journal of pharmacology and experimental therapeutics.

Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes.

R. Branch, F. Guengerich, G. Wilkinson, 1987, The Journal of pharmacology and experimental therapeutics.

Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia

S. Hall, K. McCammack, Akinbode Egbelakin, 2011, Pediatric blood & cancer.

In vivo effect of clarithromycin on multiple cytochrome P450s.

J. Gorski, B. Haehner‐Daniels, S. Hall, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity.

D. Jones, J. Gorski, S. Hall, 1996, Journal of chromatography. B, Biomedical applications.

Effect of St John's wort on the pharmacokinetics of fexofenadine

Shiew-Mei Huang, L. Lesko, Zaiqi Wang, 2002, Clinical pharmacology and therapeutics.

Association Between the CYP3A5 Genotype and Blood Pressure

N. Fineberg, D. O'Connor, Lang Li, 2005, Hypertension.

Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N‐demethylation

D. Jones, J. Gorski, S. Hall, 1996, Clinical pharmacology and therapeutics.

DEXTROMETHORPHAN TO DEXTRORPHAN URINARY METABOLIC RATIO DOES NOT REFLECT DEXTROMETHORPHAN ORAL CLEARANCE

Lang Li, J. Gorski, S. Hall, 2005, Drug Metabolism and Disposition.